Zhitong Finance App News, Conoa-B (02162.HK) issued an announcement regarding the latest clinical developments in CMG901 (also known as sonesitatug vedotin, AZD0901), in cooperation between the Group and AstraZeneca AB (AstraZeneca, a global biopharmaceutical company). The positive top-line results announced in the Clarity-Gastric01 global phase III clinical trial showed that CMG901 (sonesitatug vedotin, AZD0901) showed statistically significant and clinically significant overall survival (OS) improvements in second-line and late-line Claudin 18.2 (CLDN18.2) positive advanced gastric cancer patients compared with the treatment options selected by the researchers. The test included patients with locally advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, or esophageal adenocarcinoma (EAC). The enrollment criteria were at least 25% of tumor cells expressing CLDN 18.2 at any intensity of staining. It is estimated that approximately 60% of gastric cancers/GEJ cancers express CLDN 18.2 in ≥ 25% of tumor cells. In the US, the European Union, China, and Japan, about 183,500 patients receive second-line and late-line treatment for advanced or metastatic gastric cancer/GEJ cancer that is CLDN 18.2 positive and HER2 negative each year.

Zhitong Finance App News, Conoa-B (02162.HK) issued an announcement regarding the latest clinical developments in CMG901 (also known as sonesitatug vedotin, AZD0901), in cooperation between the Group and AstraZeneca AB (AstraZeneca, a global biopharmaceutical company). The positive top-line results announced in the Clarity-Gastric01 global phase III clinical trial showed that CMG901 (sonesitatug vedotin, AZD0901) showed statistically significant and clinically significant overall survival (OS) improvements in second-line and late-line Claudin 18.2 (CLDN18.2) positive advanced gastric cancer patients compared with the treatment options selected by the researchers. The test included patients with locally advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, or esophageal adenocarcinoma (EAC). The enrollment criteria were at least 25% of tumor cells expressing CLDN 18.2 at any intensity of staining. It is estimated that approximately 60% of gastric cancers/GEJ cancers express CLDN 18.2 in ≥ 25% of tumor cells. In the US, the European Union, China, and Japan, about 183,500 patients receive second-line and late-line treatment for advanced or metastatic gastric cancer/GEJ cancer that is CLDN 18.2 positive and HER2 negative each year.